Medical - Devices · NASDAQ
Current Price
$155.17
Intrinsic Value
$145.46
-6.7% margin of safety
As of 2026-11-20, the base-case DCF model estimates the intrinsic value of Align Technology, Inc. (ALGN) at $145.46 per share, compared with a market price of $155.17, a margin of safety of -6.7%. The base case assumes 2.8% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $116.67 to $178.73. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
At $155.17, ALGN trades about 6.7% above the base-case intrinsic value estimate, a modest premium. By this model the price sits within a normal band, though faster growth than assumed would change the picture.
COMPETITIVE MOAT
↑Strong Brand Recognition and Loyalty
Align's Invisalign brand is highly recognized and trusted by both dentists and patients. This strong brand equity creates significant customer loyalty and makes it difficult for competitors to gain market share.
↑Proprietary Technology and Manufacturing
The company possesses proprietary 3D scanning, imaging, and manufacturing technologies. This technological advantage allows for precise and efficient production of custom aligners, creating a barrier to entry.
↑Extensive Clinician Training and Support
Align has invested heavily in training and supporting dental professionals on its systems. This creates high switching costs for dentists who are integrated into Align's ecosystem and workflows.
INVESTMENT RISKS
↓Slowing Growth and Lowered Sales Outlook
The recent lowered 2026 sales outlook indicates potential market saturation or increased competitive pressures impacting future revenue growth. This suggests a deceleration in their core business.
↓Dependence on Dental Professional Adoption
Align's success is heavily reliant on dentists recommending and utilizing their products. Any shift in dentist preference or adoption of competing technologies poses a significant risk.
↓Regulatory Scrutiny and Compliance
As a medical device company, Align is subject to stringent regulatory oversight. Changes in regulations or compliance issues could impact product development, manufacturing, and market access.
Base case
Intrinsic Value
$145.46
Margin of safety
-6.7%
Expected annual return
-1.3%
Base case assumptions: 2.8% annual growth, 10.0% discount rate, 18.15x exit multiple, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Align Technology, Inc. respond.
Open DCF Calculator for ALGNAlign Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go. Additional non-case products include retention devices, fees for Invisalign training, and sales of ancillary items such as cleaning materials and adjustment tools used by dental practitioners during treatment. The Scanners and Services segment centers around the iTero scanner, a unified hardware platform offering various software applications for both restorative and orthodontic procedures. It supplies specialized restorative software to general dentists, prosthodontists, periodontists, and oral surgeons, as well as distinct software for orthodontists to manage digital patient records, perform diagnoses, and facilitate the fabrication of printed models and retainers. This segment also provides computer-aided design and manufacturing (CAD/CAM) services, along with supplementary products like disposable covers for the scanner wand and iTero models and dies. Furthermore, it includes third-party scanners and digital scan solutions, the Invisalign Outcome Simulator (a chair-side and cloud-based application for the iTero scanner), the Invisalign Progress Assessment tool, and TimeLapse technology, which enables clinicians to compare a patient's historical 3D scans against current data. Align Technology distributes its products worldwide, with a strong presence in the United States, Switzerland, and China. Founded in 1997, the company is headquartered in Tempe, Arizona.
Revenue/Share (TTM)
$58.58
FCF/Share (TTM)
$8.49
ROIC (TTM)
10.3%
ROE (TTM)
11.8%
P/FCF
18.2x
EV/EBITDA
13.3x
FCF Yield
5.51%
Debt/Equity
0.03x
Based on trailing twelve-month data, ALGN shows a free cash flow per share of $8.49 and a ROIC of 10.3%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 18.2x and FCF yield of 5.51% are important context metrics when evaluating ALGN's stock valuation relative to peers.
Align Technology, Inc. currently generates $8.49 in free cash flow per share. At the current price of $155.17, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
ALGN trades at a P/FCF ratio of 18.2x with a free cash flow yield of 5.51%. This P/FCF is in a moderate range. However, whether ALGN is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
To perform a DCF valuation on Align Technology, Inc.: (1) Start with the trailing free cash flow per share ($8.49) as the base, (2) project future FCF growth over 5-10 years based on Medical - Devices industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting ALGN's risk profile — with a debt-to-equity of 0.03x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Align Technology, Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Devices trends, then discounting those amounts to today's dollars. ALGN's ROIC of 10.3% shows moderate capital returns.
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For ALGN, with a debt-to-equity ratio of 0.03x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 13.3x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
DCF and P/E value ALGN with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.